肿瘤多药耐药逆转剂的研究进展  

The development of the reversal of the tumor multidrug resistance

作　　者：戴春岭[1] 符立梧[1] 

机构地区：[1]中山大学肿瘤防治中心,广东广州510060

出　　处：《中国药理学通报》2005年第5期513-518,共6页Chinese Pharmacological Bulletin

基　　金：广东省自然科学基金资助项目(No021813);国家自然科学基金资助项目(No30371659)

摘　　要：肿瘤细胞产生的多药耐药(multidrugresistanceMDR)已成为当前影响肿瘤化学治疗疗效的主要障碍。尽管MDR产生机制复杂,但是由mdr1基因编码的P糖蛋白(PglycoproteinPgp)的过表达是产生MDR的主要原因。寻找低毒有效的MDR逆转剂是提高化疗疗效的一个重要方法,是化疗领域亟需解决的问题。Multidrug resistance(MDR)of tumor cells has become the main impediment that influence the curative effect of cancer chemotherapy. Although there are many mechanisms can generate the multidrug resistance, the overexpression of P-glycoprotein encoded by the multidrug resistance-1(mdr1) gene is the main cause in the formation of MDR. Seaching for innocuous and effective reversal of MDR is not only a method of improving the efficiency of cancer chemotherapy but also the problem desiderated to be resolved in chemotherapy domain.

关 键 词：多药耐药 P-糖蛋白 逆转剂 肿瘤 治疗 

分 类 号：R-05[医药卫生] R730.5